Robert Baird Cuts Amgen to “Neutral”; Recent Rally Overdone? (AMGN)

Biotech giant Amgen, Inc. (AMGN) on Wednesday caught a big downgrade from analysts at Robert W. Baird.

The firm cut its rating on AMGN from “Outperform” to “Neutral” while lowering its price target from $84 to $83. That new target suggests zero upside to the stock’s Tuesday closing price of $83.94.

A Robert Baird analyst commented, “We agree AMGN’s defensive nature, increased dividend and strong cash flow remain considerations for large-cap managers making cross-sector choices. However, from our vantage point, given the stock’s +75% move since August 2011, this story appears to have largely played out for the near/intermediate term.”

Amgen shares were mostly flat in premarket trading Wednesday.

The Bottom Line
Shares of Amgen (AMGN) have a 1.72% dividend yield, based on last night’s closing stock price of $83.94. The stock has technical support in the $76-$80 price area. The shares are trading at all-time highs.

Amgen, Inc. (AMGN) is not recommended at this time, holding a DARS™ Rating of 3.4 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here